DOI: 10.1128/AAC.01715-18
Article Information
PubMed
Published By
History
- Received August 14, 2018
- Returned for modification October 3, 2018
- Accepted November 4, 2018
- Published online January 29, 2019.
Copyright & Usage
Copyright © 2019 Viriyakosol et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Article Versions
- Accepted Manuscript version (November 19, 2018).
- You are viewing the most recent version of this article.
Author Information
- Suganya Viriyakosola,
- Mili Kapoorb,
- Sharon Okamotoc,
- Jonathan Covelb,
- Quinlyn A. Soltowb,
- Michael Trzossb,
- Karen Joy Shawb and
- Joshua Fierera,b
- aVA Healthcare, San Diego, California, USA
- bAmplyx Pharmaceuticals, San Diego, California, USA
- cDivision of Infectious Diseases, Department of Medicine, UC San Diego School of Medicine, San Diego, California, USA
- Address correspondence to Karen Joy Shaw, kshaw{at}amplyx.com, or Joshua Fierer, jfierer{at}ucsd.edu.
Citation Viriyakosol S, Kapoor M, Okamoto S, Covel J, Soltow QA, Trzoss M, Shaw KJ, Fierer J. 2019. APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia. Antimicrob Agents Chemother 63:e01715-18. https://doi.org/10.1128/AAC.01715-18.
